US FDA declines full approval for Intercept's liver disease drug

Published on 12 Nov 2024 on Reuters

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept...

Read the rest of the article

Start tracking your investments with Statfolio

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim...

Benzinga · via AOL 15 Nov 2024

In the wake of Donald Trump’s recent election victory, companies are rushing to tap into the US b...

Benzinga 15 Nov 2024

Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the...

GuruFocus.com · via Yahoo Finance 13 Nov 2024

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept...

Reuters 12 Nov 2024

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported...

Benzinga · via Yahoo Finance 7 Nov 2024

Gilead Sciences Inc (GILD) reports robust Q3 performance with significant gains in HIV and oncolo...

GuruFocus.com · via Yahoo Finance 7 Nov 2024

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported...

Benzinga · via AOL 7 Nov 2024

In recent activity reported by Gilead Sciences, Inc. (NASDAQ:GILD), Chief Medical (TASE:PMCN)...

Investing.com 7 Nov 2024

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew p...

Market Watch 6 Nov 2024

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we ar...

Insider Monkey · via Yahoo Finance 4 Nov 2024